Research ArticleClinical Investigation
Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 2—Technical)
Fabien Ricard, Sally Barrington, Ron Korn, Guenther Brueggenwerth, Judith Trotman, Bruce Cheson, Gilles Salles, Larry Schwartz, Greg Goldmacher, Rudresh Jarecha, Jayant Narang, Florence Broussais, Paul Galette, Min Liu, Surabhi Bajpai, Eric Perlman, Julie Gillis, Ira Smalberg, Pierre Terve, Gudrun Zahlmann and Annette Schmid
Journal of Nuclear Medicine February 2023, 64 (2) 239-243; DOI: https://doi.org/10.2967/jnumed.122.264124
Fabien Ricard
1Relay Therapeutics, Cambridge, Massachusetts;
Sally Barrington
2King’s College London and Guy’s and St. Thomas’ PET Centre, School of Biomedical Engineering and Imaging Sciences, King’s College London, King’s Health Partners, London, United Kingdom;
Ron Korn
3Adjunct Faculty TGEN/City of Hope and Imaging Endpoints Core Lab, Scottsdale, Arizona;
Guenther Brueggenwerth
4Bayer AG, Berlin, Germany;
Judith Trotman
5Concord Repatriation General Hospital, University of Sydney, Concord, Australia;
Bruce Cheson
6Lymphoma Research Foundation, New York, New York;
Gilles Salles
7Department of Medicine, Memorial Sloan Kettering Cancer Center and Weil Cornell Medicine, New York, New York;
Larry Schwartz
8Department of Radiology, Columbia University College of Physicians and Surgeons and Radiologist-in-Chief, The New York Presbyterian Hospital, Columbia, New York;
Greg Goldmacher
9Merck & Co, Inc., Kenilworth, New Jersey;
Rudresh Jarecha
10Deciphera Pharmaceuticals LLC, Waltham, Massachusetts;
Jayant Narang
11Takeda Pharmaceutical Company Ltd, Cambridge, Massachusetts;
Florence Broussais
12Lymphoma Study Association Research Center LYSARC, Pierre Benite, France Calyx International, Billerica, Massachusetts;
Paul Galette
13GSK, Collegeville, Pennsylvania;
Min Liu
14Autolus Therapeutics, London, United Kingdom;
Surabhi Bajpai
15Calyx International, Billerica, Massachusetts;
Eric Perlman
16Perlman Advisory Group LLC, Boynton Beach, Florida;
Julie Gillis
17Merigold LLC, Branford, Connecticut;
Ira Smalberg
18Saint John’s Cancer Institute and Tower Imaging Medical Group, Sherman Oaks, California;
Pierre Terve
19KEOSYS Medical Imaging, Saint Herblain, France; and
Gudrun Zahlmann
20QIBA/RSNA, Radiological Society of North America, Oak Brook, Illinois
Annette Schmid
11Takeda Pharmaceutical Company Ltd, Cambridge, Massachusetts;
Article Figures & Data
Figures
Additional Files
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 64, Issue 2
February 1, 2023
Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 2—Technical)
Fabien Ricard, Sally Barrington, Ron Korn, Guenther Brueggenwerth, Judith Trotman, Bruce Cheson, Gilles Salles, Larry Schwartz, Greg Goldmacher, Rudresh Jarecha, Jayant Narang, Florence Broussais, Paul Galette, Min Liu, Surabhi Bajpai, Eric Perlman, Julie Gillis, Ira Smalberg, Pierre Terve, Gudrun Zahlmann, Annette Schmid
Journal of Nuclear Medicine Feb 2023, 64 (2) 239-243; DOI: 10.2967/jnumed.122.264124
Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 2—Technical)
Fabien Ricard, Sally Barrington, Ron Korn, Guenther Brueggenwerth, Judith Trotman, Bruce Cheson, Gilles Salles, Larry Schwartz, Greg Goldmacher, Rudresh Jarecha, Jayant Narang, Florence Broussais, Paul Galette, Min Liu, Surabhi Bajpai, Eric Perlman, Julie Gillis, Ira Smalberg, Pierre Terve, Gudrun Zahlmann, Annette Schmid
Journal of Nuclear Medicine Feb 2023, 64 (2) 239-243; DOI: 10.2967/jnumed.122.264124
Jump to section
Related Articles
Cited By...
- No citing articles found.